Related Experiment Video
Updated: Jul 4, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Biologic response modifier therapy for psoriatic ocular inflammatory disease
Nancy Huynh1, Rene A Cervantes-Castaneda, Pooja Bhat
1Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts 02142, USA.
Ocular Immunology and Inflammation
|June 24, 2008
Summary
Biologic response modifiers (BRMs) show promise in treating psoriatic ocular inflammatory disease. Seven of eight patients achieved remission, suggesting BRMs can be a valuable addition to treatment plans.
Area of Science:
- Ophthalmology
- Rheumatology
- Immunology
Background:
- Psoriatic ocular inflammatory disease presents a significant challenge in patient management.
- Biologic response modifiers (BRMs) offer a targeted approach to inflammatory conditions.
Purpose of the Study:
- To assess the effectiveness and safety of BRMs for psoriatic ocular inflammatory disease.
- To evaluate intraocular inflammation control, visual acuity changes, and adverse events.
Main Methods:
- Retrospective review of 8 patients with psoriatic ocular inflammatory disease.
- Patients received either adalimumab or infliximab.
- Outcomes included inflammation control, visual acuity, and safety monitoring.
Main Results:
- Seven out of eight patients achieved remission of ocular inflammation.
- Visual acuity outcomes varied, with improvement in 2, deterioration in 2, and stability in 4 patients.
- Commonly used BRMs were adalimumab and infliximab, with a mean therapy duration of 6.1 months.
Conclusions:
- BRMs demonstrate potential as an effective adjunctive therapy for psoriatic ocular inflammatory disease.
- Further research is warranted to optimize BRM use in this patient population.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:22Microbiome of the Eye
The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...